ticlopidine has been researched along with Chronic Illness in 54 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding." | 9.14 | Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010) |
| "This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin." | 9.10 | A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002) |
| "Our aim was to identify risk factors for acute gastrointestinal (GI) bleeding in patients with myocardial infarction (MI) who were prescribed clopidogrel following hospital discharge." | 7.80 | Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. ( Cuschieri, JR; Drawz, P; Falck-Ytter, Y; Wong, RC, 2014) |
| "The benefits of taking of aspirin, clopidogrel, and warfarin in relation to cardiovascular mortality and re-hospitalization in chronic heart failure (HF) patients have been called into question." | 7.78 | Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. ( Celikyurt, U; Ertaş, G; Kılıç, T; Kozdağ, G; Sahin, T; Ural, D; Yaymacı, M, 2012) |
| "To describe ticlopidine related microscopic colitis and to assess the occurrence of apoptosis in the colon epithelium." | 7.70 | Ticlopidine induced colitis: a histopathological study including apoptosis. ( Berrebi, D; Dauge, MC; Flejou, JF; Peuchmaur, M; Potet, F; Sautet, A, 1998) |
| "Lymphocytic colitis is a chronic inflammatory colonic disease characterized by watery diarrhea and a dense infiltration of the colonic mucosa with lymphocytes." | 6.40 | Lymphocytic colitis, induced by ticlopidine. ( Bartz, KO; Feurle, GE; Schmitt-Gräff, A, 1999) |
| "Aspirin was given as 160 mg/day and clopidogrel as 300 mg loading dose followed by 75 mg/day." | 5.35 | Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. ( Agewall, S; Berglund, M; Gordon, A; Saha, S; Sylvén, C, 2008) |
| "Lymphocytic colitis is a clinico-pathological syndrome characterized by chronic diarrhea, normal endoscopy, diffuse colonic mucosal inflammatory changes." | 5.30 | [Ticlopidine-induced lymphocytic colitis]. ( Abd Alsamad, I; Chousterman, M; Cohen, C; Fléjou, JF; Hagege, H; Nahon, S; Rosa, I, 1999) |
| "In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding." | 5.14 | Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010) |
| "This study was designed to investigate whether or not combination aspirin-clopidogrel therapy would reduce markers of thrombogenesis and platelet activation in atrial fibrillation (AF), in a manner similar to warfarin." | 5.10 | A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. ( Blann, AD; Chin, BS; Kamath, S; Lip, GY, 2002) |
| " No data exist about the impact of HRPR after 600 mg clopidogrel loading on long-term clinical outcome in patients with diabetes mellitus and treated with percutaneous coronary angioplasty (PCI) for chronic total occlusion (CTO)." | 3.81 | Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. ( Abbate, R; Antoniucci, D; Cantini, G; Carrabba, N; Cerisano, G; Comito, V; Gensini, GF; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Parodi, G; Valenti, R; Vergara, R, 2015) |
| "Our aim was to identify risk factors for acute gastrointestinal (GI) bleeding in patients with myocardial infarction (MI) who were prescribed clopidogrel following hospital discharge." | 3.80 | Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel. ( Cuschieri, JR; Drawz, P; Falck-Ytter, Y; Wong, RC, 2014) |
| "The benefits of taking of aspirin, clopidogrel, and warfarin in relation to cardiovascular mortality and re-hospitalization in chronic heart failure (HF) patients have been called into question." | 3.78 | Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure. ( Celikyurt, U; Ertaş, G; Kılıç, T; Kozdağ, G; Sahin, T; Ural, D; Yaymacı, M, 2012) |
| "Twenty-seven patients with chronic myeloproliferative disorders and in vitro evidence of platelet hyperactivity on whole blood platelet lumi-aggregometry were commenced on anti-platelet therapy comprising aspirin, clopidogrel, and/or odorless garlic and the studies were repeated to assess the efficacy of the therapeutic agent(s)." | 3.73 | Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders. ( Gemmell, R; Hartwell, T; Manoharan, A, 2006) |
| " Citrated blood samples were collected from 62 patients with chronic cerebral infarction (CCI), of whom 19 patients were treated with ticlopidine, and from 9 healthy subjects." | 3.72 | Simple, rapid, and automated method for detection of hyperaggregability of platelets using a hematology analyzer. ( Ando, Y; Miyachi, H; Shimizu, M; Shinohara, Y; Yamamoto, M, 2003) |
| "To describe ticlopidine related microscopic colitis and to assess the occurrence of apoptosis in the colon epithelium." | 3.70 | Ticlopidine induced colitis: a histopathological study including apoptosis. ( Berrebi, D; Dauge, MC; Flejou, JF; Peuchmaur, M; Potet, F; Sautet, A, 1998) |
| "In order to find out the difference between cilostazol and ticlopidine hydrochloride in the cerebral vasodilating effect in the chronic stage of cerebral infarction, cerebral blood flows were measured while the patients were on ticlopidine hydrochloride and after ticlopidine hydrochloride was switched to cilostazol." | 3.70 | Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation. ( Mochizuki, Y; Oishi, M; Satoh, Y; Shikata, E, 2000) |
| "Combination antiplatelet agents, particularly aspirin and ticlopidine, have found increased use in the prevention of arterial thrombosis." | 3.70 | A pharmacodynamic study of clopidogrel in chronic hemodialysis patients. ( Fiore, L; Hasbargen, JA; Kaufman, JS; O'Connor, TZ; Perdriset, G, 2000) |
| "Six years later after a left cerebral transient ischemic attack aspirin was replaced by ticlopidine." | 2.41 | [Cholestatic hepatitis as a rare side effect of therapy with ticlopidine]. ( Auer, J; Berent, R; Haidenthaler, A; Hinterholzer, G; Höbling, W; Knoflach, P, 2000) |
| "Lymphocytic colitis is a chronic inflammatory colonic disease characterized by watery diarrhea and a dense infiltration of the colonic mucosa with lymphocytes." | 2.40 | Lymphocytic colitis, induced by ticlopidine. ( Bartz, KO; Feurle, GE; Schmitt-Gräff, A, 1999) |
| "Aspirin was given as 160 mg/day and clopidogrel as 300 mg loading dose followed by 75 mg/day." | 1.35 | Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris. ( Agewall, S; Berglund, M; Gordon, A; Saha, S; Sylvén, C, 2008) |
| "Lymphocytic colitis is a clinico-pathological syndrome characterized by chronic diarrhea, normal endoscopy, diffuse colonic mucosal inflammatory changes." | 1.30 | [Ticlopidine-induced lymphocytic colitis]. ( Abd Alsamad, I; Chousterman, M; Cohen, C; Fléjou, JF; Hagege, H; Nahon, S; Rosa, I, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (14.81) | 18.7374 |
| 1990's | 14 (25.93) | 18.2507 |
| 2000's | 17 (31.48) | 29.6817 |
| 2010's | 15 (27.78) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cuschieri, JR | 1 |
| Drawz, P | 1 |
| Falck-Ytter, Y | 1 |
| Wong, RC | 1 |
| Rebrova, TIu | 1 |
| Muslimova, EF | 1 |
| Afanas'ev, SA | 1 |
| Sergienko, TN | 1 |
| Repin, AN | 1 |
| Valenti, R | 1 |
| Cantini, G | 1 |
| Marcucci, R | 1 |
| Marrani, M | 1 |
| Migliorini, A | 1 |
| Carrabba, N | 1 |
| Comito, V | 1 |
| Vergara, R | 1 |
| Cerisano, G | 1 |
| Parodi, G | 1 |
| Abbate, R | 1 |
| Gori, AM | 1 |
| Gensini, GF | 1 |
| Antoniucci, D | 1 |
| Walter, T | 1 |
| Szabo, S | 1 |
| Kazmaier, S | 1 |
| Swoboda, S | 1 |
| Suselbeck, T | 1 |
| Brueckmann, M | 1 |
| Borggrefe, M | 1 |
| Beyer, ME | 1 |
| Hoffmeister, HM | 1 |
| Massie, BM | 1 |
| Collins, JF | 1 |
| Ammon, SE | 1 |
| Armstrong, PW | 1 |
| Cleland, JG | 1 |
| Ezekowitz, M | 1 |
| Jafri, SM | 1 |
| Krol, WF | 1 |
| O'Connor, CM | 1 |
| Schulman, KA | 1 |
| Teo, K | 1 |
| Warren, SR | 1 |
| Sambola, A | 1 |
| Ferreira-González, I | 1 |
| Angel, J | 1 |
| Alfonso, F | 1 |
| Maristany, J | 1 |
| Rodríguez, O | 1 |
| Bueno, H | 1 |
| López-Minguez, JR | 1 |
| Zueco, J | 1 |
| Fernández-Avilés, F | 1 |
| San Román, A | 1 |
| Prendergast, B | 1 |
| Mainar, V | 1 |
| García-Dorado, D | 1 |
| Tornos, P | 1 |
| Buriachkovskaia, LI | 1 |
| Uchitel', IA | 1 |
| Sumarokov, AV | 1 |
| Popov, EG | 1 |
| Kan, LP | 1 |
| Chu, KM | 1 |
| Lin, GM | 1 |
| Ponikowski, P | 1 |
| Ronco, C | 1 |
| Anker, SD | 1 |
| James, S | 1 |
| Budaj, A | 1 |
| Aylward, P | 1 |
| Buck, KK | 1 |
| Cannon, CP | 1 |
| Cornel, JH | 1 |
| Harrington, RA | 1 |
| Horrow, J | 1 |
| Katus, H | 1 |
| Keltai, M | 1 |
| Lewis, BS | 1 |
| Parikh, K | 1 |
| Storey, RF | 1 |
| Szummer, K | 1 |
| Wojdyla, D | 1 |
| Wallentin, L | 1 |
| Park, KW | 1 |
| Park, JJ | 1 |
| Jeon, KH | 1 |
| Kang, SH | 1 |
| Oh, IY | 1 |
| Yang, HM | 1 |
| Cho, HJ | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Oh, BH | 1 |
| Park, YB | 1 |
| Kim, HS | 1 |
| Chaiyakunapruk, N | 1 |
| Thanarungroj, A | 1 |
| Cheewasithirungrueng, N | 1 |
| Srisupha-olarn, W | 1 |
| Nimpitakpong, P | 1 |
| Dilokthornsakul, P | 1 |
| Jeanpeerapong, N | 1 |
| Gao, F | 1 |
| Zhou, YJ | 1 |
| Wang, ZJ | 1 |
| Yang, SW | 1 |
| Nie, B | 1 |
| Liu, XL | 1 |
| Jia, de A | 1 |
| Yan, ZX | 1 |
| Htun, P | 1 |
| Fateh-Moghadam, S | 1 |
| Bischofs, C | 1 |
| Banya, W | 1 |
| Müller, K | 1 |
| Bigalke, B | 1 |
| Stellos, K | 1 |
| May, AE | 1 |
| Flather, M | 1 |
| Gawaz, M | 1 |
| Geisler, T | 1 |
| Diener, HC | 1 |
| Weber, R | 1 |
| Weimar, C | 1 |
| Röther, J | 1 |
| Kozdağ, G | 1 |
| Yaymacı, M | 1 |
| Ertaş, G | 1 |
| Celikyurt, U | 1 |
| Sahin, T | 1 |
| Kılıç, T | 1 |
| Ural, D | 1 |
| Alexopoulos, D | 1 |
| Xanthopoulou, I | 1 |
| Davlouros, P | 1 |
| Plakomyti, TE | 1 |
| Panagiotou, A | 1 |
| Mavronasiou, E | 1 |
| Hahalis, G | 1 |
| Basra, SS | 1 |
| Tsai, P | 1 |
| Lakkis, NM | 1 |
| Woo, JS | 1 |
| Kim, W | 1 |
| Lee, SR | 1 |
| Jung, KH | 1 |
| Kim, WS | 1 |
| Lew, JH | 1 |
| Lee, TW | 1 |
| Lim, CK | 1 |
| Kamath, S | 1 |
| Blann, AD | 1 |
| Chin, BS | 1 |
| Lip, GY | 1 |
| Shimizu, M | 1 |
| Yamamoto, M | 1 |
| Miyachi, H | 1 |
| Shinohara, Y | 1 |
| Ando, Y | 1 |
| Jochmann, N | 1 |
| Stangl, K | 1 |
| Garbe, E | 1 |
| Baumann, G | 1 |
| Stangl, V | 1 |
| Maman, L | 1 |
| Stieltjes, N | 1 |
| Galeazzi, JM | 1 |
| Kalafat, M | 1 |
| Alantar, A | 1 |
| Manoharan, A | 1 |
| Gemmell, R | 1 |
| Hartwell, T | 1 |
| Saha, S | 1 |
| Berglund, M | 1 |
| Sylvén, C | 1 |
| Gordon, A | 1 |
| Agewall, S | 1 |
| Tu, X | 1 |
| Chen, X | 1 |
| Xie, Y | 1 |
| Shi, S | 1 |
| Wang, J | 1 |
| Chen, Y | 1 |
| Li, J | 1 |
| Widimsky, P | 1 |
| Motovská, Z | 1 |
| Simek, S | 1 |
| Kala, P | 1 |
| Pudil, R | 1 |
| Holm, F | 1 |
| Petr, R | 1 |
| Bílková, D | 1 |
| Skalická, H | 1 |
| Kuchynka, P | 1 |
| Poloczek, M | 1 |
| Miklík, R | 1 |
| Maly, M | 1 |
| Aschermann, M | 1 |
| Giardina, MG | 1 |
| Matarazzo, M | 1 |
| Cacciatore, L | 1 |
| De Marco, F | 1 |
| Katsumura, T | 1 |
| Mishima, Y | 1 |
| Kamiya, K | 1 |
| Sakaguchi, S | 1 |
| Tanabe, T | 1 |
| Sakuma, A | 1 |
| Kohriyama, T | 1 |
| Tanaka, E | 1 |
| Katayama, S | 1 |
| Yamamura, Y | 1 |
| Nakamura, S | 1 |
| Hoffman, HS | 1 |
| Butensky, MS | 1 |
| Valdés Oliveras, M | 1 |
| Barenys de Lacha, M | 1 |
| Abad Lacruz, A | 1 |
| Admetlla Falgueras, M | 1 |
| Suslina, ZA | 1 |
| Ionova, VG | 1 |
| Nikitenko, NIu | 1 |
| Maksimova, MIu | 1 |
| Fraga, MD | 1 |
| García, B | 1 |
| Agud, JL | 1 |
| Marco, J | 1 |
| de Juana, P | 1 |
| Cervero, M | 1 |
| Anzuini, A | 1 |
| Rosanio, S | 1 |
| Legrand, V | 1 |
| Tocchi, M | 1 |
| Coppi, R | 1 |
| Marazzi, G | 1 |
| Vicedomini, G | 1 |
| Pagnotta, P | 1 |
| Montorfano, M | 1 |
| Bonnier, H | 1 |
| Sheiban, I | 1 |
| Kulbertus, HE | 1 |
| Chierchia, SL | 1 |
| Berrebi, D | 1 |
| Sautet, A | 1 |
| Flejou, JF | 2 |
| Dauge, MC | 1 |
| Peuchmaur, M | 1 |
| Potet, F | 1 |
| Koskin, VM | 1 |
| Bogdanets, LI | 1 |
| Bouvet, C | 1 |
| Bellaiche, G | 1 |
| Slama, R | 1 |
| Auberger, E | 1 |
| Lachgar, T | 1 |
| Nury, B | 1 |
| Roche-Sicot, J | 1 |
| Rosa, I | 1 |
| Nahon, S | 1 |
| Cohen, C | 1 |
| Abd Alsamad, I | 1 |
| Hagege, H | 1 |
| Chousterman, M | 1 |
| Feurle, GE | 1 |
| Bartz, KO | 1 |
| Schmitt-Gräff, A | 1 |
| Oishi, M | 1 |
| Mochizuki, Y | 1 |
| Shikata, E | 1 |
| Satoh, Y | 1 |
| Berent, R | 1 |
| Hinterholzer, G | 1 |
| Höbling, W | 1 |
| Auer, J | 1 |
| Haidenthaler, A | 1 |
| Knoflach, P | 1 |
| Kaufman, JS | 1 |
| Fiore, L | 1 |
| Hasbargen, JA | 1 |
| O'Connor, TZ | 1 |
| Perdriset, G | 1 |
| Rota Roca, MR | 1 |
| Castellote, J | 1 |
| Xiol, X | 1 |
| Sánchez Gili, M | 1 |
| Ruget, O | 1 |
| Burtin, P | 1 |
| Cérez, H | 1 |
| Calès, P | 1 |
| Boyer, J | 1 |
| Velikov, VK | 1 |
| Saltykov, BB | 1 |
| Galkina, AK | 1 |
| Kabaeva, EV | 1 |
| Frolova, AI | 1 |
| Privalova, EV | 1 |
| Savina, TS | 1 |
| Zelenchuk, NM | 1 |
| Shubina, OI | 1 |
| Iarovaia, LD | 1 |
| Chassany, O | 1 |
| Bacq, Y | 1 |
| Metman, EH | 1 |
| Gillion, JM | 1 |
| Dorval, ED | 1 |
| Jankowski, JM | 1 |
| Tomeoku, M | 1 |
| Nakase, T | 1 |
| Morita, K | 1 |
| Katou, M | 1 |
| Tesi, M | 1 |
| Bronchi, GF | 1 |
| Carini, A | 1 |
| Karavassili, M | 1 |
| Teraoka, S | 1 |
| Takahashi, K | 1 |
| Toma, H | 1 |
| Sanaka, T | 1 |
| Yamaguchi, Y | 1 |
| Tanabe, K | 1 |
| Sato, H | 1 |
| Kawaguchi, H | 1 |
| Oba, S | 1 |
| Nakajima, I | 1 |
| Khurmi, NS | 2 |
| Bowles, MJ | 2 |
| Kohli, RS | 1 |
| Raftery, EB | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CSP #442 - Warfarin and Antiplatelet Therapy Study in Patients With Congestive Heart Failure (WATCH)[NCT00007683] | Phase 3 | 1,587 participants (Anticipated) | Interventional | 1998-10-31 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388] | Phase 3 | 74 participants (Actual) | Interventional | 2017-02-07 | Completed | ||
| Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470] | Phase 4 | 85 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
7 reviews available for ticlopidine and Chronic Illness
| Article | Year |
|---|---|
Meta-analysis of the combination of warfarin and dual antiplatelet therapy after coronary stenting in patients with indications for chronic oral anticoagulation.
Topics: Administration, Oral; Anticoagulants; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogre | 2011 |
Secondary prevention in the acute and early chronic phase after ischaemic stroke and transient ischaemic attacks with antiplatelet drugs--is antiplatelet monotherapy still reasonable?
Topics: Abciximab; Acute Disease; Antibodies, Monoclonal; Aspirin; Chronic Disease; Clopidogrel; Delayed-Act | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; | 2011 |
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Aspir | 2005 |
[Ticlid: clinical effectiveness and significance in combined conservative treatment of chronic obliterating diseases of lower limb arteries].
Topics: Arterial Occlusive Diseases; Chronic Disease; Humans; Leg; Platelet Aggregation Inhibitors; Safety; | 1998 |
Lymphocytic colitis, induced by ticlopidine.
Topics: Biopsy; Chronic Disease; Colitis; Colon; Colonoscopy; Diarrhea; Humans; Intestinal Mucosa; Lymphocyt | 1999 |
[Cholestatic hepatitis as a rare side effect of therapy with ticlopidine].
Topics: Aged; Atrial Fibrillation; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Cholestasis; Chro | 2000 |
14 trials available for ticlopidine and Chronic Illness
| Article | Year |
|---|---|
Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary heart disease.
Topics: Aged; Angina Pectoris; Aspirin; Cell Adhesion Molecules; Chronic Disease; Clopidogrel; Double-Blind | 2008 |
Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
[Difficulties in evaluating the efficacy of antiplatelet therapy in clinical practice].
Topics: Adult; Aspirin; Chronic Disease; Clopidogrel; Data Interpretation, Statistical; Drug Resistance; Dru | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Prasugrel overcomes high on-clopidogrel platelet reactivity in chronic coronary artery disease patients more effectively than high dose (150 mg) clopidogrel.
Topics: Aged; Chronic Disease; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Mal | 2011 |
Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: results of the effect of platelet inhibition according to clopidogrel dose in patients with chronic kidney di
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Chronic Disease; Cilostazol; Clopidogrel; Coronary Arte | 2011 |
A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Chronic Disease; Clopidogrel; | 2002 |
Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Chronic Disease; Clopid | 2008 |
Therapeutic effect of ticlopidine, a new inhibitor of platelet aggregation, on chronic arterial occlusive diseases, a double-blind study versus placebo.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Double-Bli | 1982 |
[Antiplatelet therapy in patients with cerebral thrombosis at the chronic phase--assessment of its effect on coagulation and fibrinolytic parameters].
Topics: Aged; Aspirin; Blood Coagulation; Cerebrovascular Disorders; Chronic Disease; Fibrinolysis; Humans; | 1994 |
[Immediate and long-term clinical and angiographic results of the Wiktor stent in the treatment of chronic coronary occlusions].
Topics: Analysis of Variance; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chronic Disease; Coro | 1997 |
Therapy of atherosclerotic arteriopathy of lower limbs. Aspects and results.
Topics: Acute Disease; Arteriosclerosis; Chronic Disease; Clinical Trials as Topic; Glycosaminoglycans; Hepa | 1985 |
Does placebo improve indexes of effort-induced myocardial ischemia? An objective study in 150 patients with chronic stable angina pectoris.
Topics: Adult; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Coronary Disease; Double-Bl | 1986 |
Are anti-platelet drugs of value in the management of patients with chronic stable angina? A study with ticlopidine.
Topics: Administration, Oral; Aged; Angina Pectoris; Chronic Disease; Clinical Trials as Topic; Double-Blind | 1986 |
33 other studies available for ticlopidine and Chronic Illness
| Article | Year |
|---|---|
Risk factors for acute gastrointestinal bleeding following myocardial infarction in veteran patients who are prescribed clopidogrel.
Topics: Acute Disease; Age Factors; Aged; Anticoagulants; Chronic Disease; Clopidogrel; Female; Gastrointest | 2014 |
[Resistance to clopidogrel and polymorphism of P2RY12 and GPIIIA genes in patients with chronic coronary heart disease].
Topics: Alleles; Chronic Disease; Clopidogrel; Coronary Disease; DNA; Drug Resistance; Female; Genotype; Hum | 2013 |
Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus.
Topics: Aged; Blood Platelets; Chronic Disease; Clopidogrel; Coronary Occlusion; Diabetes Mellitus; Dose-Res | 2015 |
Therapeutic strategies after coronary stenting in chronically anticoagulated patients: the MUSICA study.
Topics: Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Chronic Disease; Clopidogrel; Coronary Disease | 2009 |
Letter by Kan et al regarding Article, "randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart failure (WATCH) trial".
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Chronic Disease; Clopidogrel; Death; Double-Blind Method; F | 2009 |
Cardiorenal syndromes--recommendations from clinical practice guidelines: the cardiologist's view.
Topics: Acute Disease; Acute Kidney Injury; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhib | 2010 |
Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.
Topics: Age Factors; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Asian People; Biomarkers; B | 2012 |
Estimation of financial burden due to oversupply of medications for chronic diseases.
Topics: Aged; Atorvastatin; Chronic Disease; Clopidogrel; Drug Costs; Female; Heptanoic Acids; Hospitals, Un | 2012 |
[Current status of medical therapy of chronic stable angina pectoris in mainland of China: the second survey].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin Receptor A | 2010 |
Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Chronic Disease; Clopidogrel; Cohort Studies; Coronar | 2011 |
Aspirin, clopidogrel, and warfarin use and outcomes in a cohort of 580 patients discharged after hospitalization for decompensated heart failure.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Aspirin; Chi-Square Distribution; Ch | 2012 |
Simple, rapid, and automated method for detection of hyperaggregability of platelets using a hematology analyzer.
Topics: Aged; Anticoagulants; Automation; Blood Cell Count; Cerebral Infarction; Chronic Disease; Citric Aci | 2003 |
Multiple teeth extractions in a patient with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), treated with ticlopidine.
Topics: CADASIL; Chronic Disease; Dental Care for Chronically Ill; Female; Hemostasis, Surgical; Hemostatics | 2006 |
Use of whole blood platelet lumi-aggregometry to optimize anti-platelet therapy in patients with chronic myeloproliferative disorders.
Topics: Aspirin; Chronic Disease; Clopidogrel; Dietary Supplements; Dose-Response Relationship, Drug; Garlic | 2006 |
Clopidogrel inhibits platelet aggregation in patients on aspirin with stable chronic angina pectoris.
Topics: Angina Pectoris; Aspirin; Chronic Disease; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggre | 2008 |
Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Biphenyl Compounds; Blood | 2008 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Ticlopidine can cause chronic diarrhoea.
Topics: Aged; Anticoagulants; Chronic Disease; Diarrhea; Humans; Male; Thiophenes; Ticlopidine | 1984 |
Severe diarrhea with Ticlid therapy.
Topics: Aged; Chronic Disease; Diarrhea; Female; Humans; Severity of Illness Index; Ticlopidine | 1994 |
[Chronic diarrhea caused by ticlopidine].
Topics: Aged; Chronic Disease; Diarrhea; Female; Humans; Ticlopidine | 1993 |
[Clinical and blood rheologic effects of ticlid in patients with cerebrovascular diseases].
Topics: Adult; Blood Coagulation Tests; Blood Viscosity; Cerebrovascular Disorders; Chronic Disease; Drug Ev | 1993 |
Severe chronic diarrhea induced by ticlopidine.
Topics: Aged; Chronic Disease; Diarrhea; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidine | 1996 |
Ticlopidine induced colitis: a histopathological study including apoptosis.
Topics: Aged; Apoptosis; Chronic Disease; Colitis; Diarrhea; DNA Nucleotidylexotransferase; Female; Humans; | 1998 |
[Lymphocytic colitis and villous atrophy after treatment with ticlopidine].
Topics: Aged; Aged, 80 and over; Arteritis; Atrophy; Chronic Disease; Colitis; Diarrhea; Duodenum; Female; F | 1998 |
[Ticlopidine-induced lymphocytic colitis].
Topics: Aged; Biopsy; Chronic Disease; Colitis; Colon; Diarrhea; Fibrinolytic Agents; Humans; Male; Platelet | 1999 |
Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation.
Topics: Aged; Carotid Arteries; Cerebral Infarction; Cerebrovascular Circulation; Chronic Disease; Cilostazo | 2000 |
A pharmacodynamic study of clopidogrel in chronic hemodialysis patients.
Topics: Adenosine Diphosphate; Arterial Occlusive Diseases; Chronic Disease; Clopidogrel; Dose-Response Rela | 2000 |
[Severe chronic diarrhea caused by ticlopidine].
Topics: Cerebrovascular Disorders; Chronic Disease; Diarrhea; Humans; Male; Middle Aged; Ticlopidine | 1992 |
[Chronic diarrhea associated with villous atrophy and lymphocytic gastritis, caused by ticlopidine].
Topics: Aged; Atrophy; Chronic Disease; Diarrhea; Duodenum; Gastritis; Humans; Male; Ticlopidine | 1992 |
[The efficacy of the antiaggregants ticlid and diabeton in correcting chronic intravascular microcoagulation of the blood in diabetic patients].
Topics: Adolescent; Adult; Aged; Blood Coagulation Tests; Chronic Disease; Diabetes Mellitus, Type 1; Diabet | 1991 |
[Severe chronic diarrhea during treatment with ticlopidine].
Topics: Aged; Chronic Disease; Diarrhea; Humans; Male; Ticlopidine | 1989 |
[Chronic disseminated intravascular coagulation due to abdominal true aneurysm in two cases--effect of anti-platelet and anti-fibrinolytic therapy].
Topics: Aged; Aorta, Abdominal; Aortic Aneurysm; Chronic Disease; Cyclohexanecarboxylic Acids; Disseminated | 1989 |
Application of prostacyclin analogue and thromboxane synthetase inhibitor to chronic vascular rejection after kidney transplantation.
Topics: Acrylates; Chronic Disease; Epoprostenol; Graft Rejection; Humans; Kidney Transplantation; Methacryl | 1987 |